These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 12784996)

  • 1. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials.
    Pavlaki M; Zucker S
    Cancer Metastasis Rev; 2003; 22(2-3):177-203. PubMed ID: 12784996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
    Zucker S; Cao J; Chen WT
    Oncogene; 2000 Dec; 19(56):6642-50. PubMed ID: 11426650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug.
    Mitsiades N; Poulaki V; Mitsiades CS; Anderson KC
    Expert Opin Investig Drugs; 2001 Jun; 10(6):1075-84. PubMed ID: 11772236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes.
    Winer A; Adams S; Mignatti P
    Mol Cancer Ther; 2018 Jun; 17(6):1147-1155. PubMed ID: 29735645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinases as therapeutic targets in cancer.
    Vihinen P; Ala-aho R; Kähäri VM
    Curr Cancer Drug Targets; 2005 May; 5(3):203-20. PubMed ID: 15892620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress in the development of matrix metalloproteinase inhibitors.
    Tu G; Xu W; Huang H; Li S
    Curr Med Chem; 2008; 15(14):1388-95. PubMed ID: 18537616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent developments in patent anti-cancer agents targeting the matrix metalloproteinases (MMPs).
    Li X; Wu JF
    Recent Pat Anticancer Drug Discov; 2010 Jun; 5(2):109-41. PubMed ID: 19951249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinase inhibitors for cancer therapy:the current situation and future prospects.
    Fingleton B
    Expert Opin Ther Targets; 2003 Jun; 7(3):385-97. PubMed ID: 12783574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of gelatinases (MMP-2 and MMP-9) for the management of hematological malignancies.
    Das S; Amin SA; Jha T
    Eur J Med Chem; 2021 Nov; 223():113623. PubMed ID: 34157437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MMP inhibitors and cancer treatment trials, limitations and hopes for the future.
    Tlatli R; El Ayeb M
    Arch Inst Pasteur Tunis; 2013; 90(1-4):3-21. PubMed ID: 26012207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix metalloproteinase inhibitors.
    Ramnath N; Creaven PJ
    Curr Oncol Rep; 2004 Mar; 6(2):96-102. PubMed ID: 14751086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix metalloproteinase inhibitors (MMPIs) as attractive therapeutic targets: Recent progress and current challenges.
    Shi Y; Ma X; Fang G; Tian X; Ge C
    NanoImpact; 2021 Jan; 21():100293. PubMed ID: 35559782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix metalloproteinase inhibitors: present achievements and future prospects.
    Denis LJ; Verweij J
    Invest New Drugs; 1997; 15(3):175-85. PubMed ID: 9387040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of MMPs in metastatic dissemination: implications for therapeutic advances.
    Raffo D; Pontiggia O; Simian M
    Curr Pharm Biotechnol; 2011 Nov; 12(11):1937-47. PubMed ID: 21470127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloproteinase inhibitors: applications in oncology.
    Yip D; Ahmad A; Karapetis CS; Hawkins CA; Harper PG
    Invest New Drugs; 1999; 17(4):387-99. PubMed ID: 10759405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix metalloproteinase and its drug targets therapy in solid and hematological malignancies: an overview.
    Chaudhary AK; Pandya S; Ghosh K; Nadkarni A
    Mutat Res; 2013; 753(1):7-23. PubMed ID: 23370482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer.
    Zhong Y; Lu YT; Sun Y; Shi ZH; Li NG; Tang YP; Duan JA
    Expert Opin Drug Discov; 2018 Jan; 13(1):75-87. PubMed ID: 29088927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer.
    Bonomi P
    Semin Oncol; 2002 Feb; 29(1 Suppl 4):78-86. PubMed ID: 11894017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An updated patent therapeutic agents targeting MMPs.
    Shi ZG; Li JP; Shi LL; Li X
    Recent Pat Anticancer Drug Discov; 2012 Jan; 7(1):74-101. PubMed ID: 21854361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility.
    Dormán G; Cseh S; Hajdú I; Barna L; Kónya D; Kupai K; Kovács L; Ferdinandy P
    Drugs; 2010 May; 70(8):949-64. PubMed ID: 20481653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.